Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DYP 688

Drug Profile

DYP 688

Alternative Names: DYP-688

Latest Information Update: 22 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action GNA11 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Uveal melanoma

Most Recent Events

  • 04 Jul 2022 Phase-I/II clinical trials in Uveal melanoma (Metastatic disease, In children, In the elderly, In adolescents, In adults) in Australia (unspecified route) (NCT05415072) (EudraCT2021-003380-95)
  • 10 Jun 2022 Novartis Pharmaceuticals plans a phase I/II trial for Uveal melanoma (Metastatic disease, In children, In adolescents, In adults, In the elderly), in June 2022 (NCT05415072) (EudraCT2021-003380-95)
  • 10 Jun 2022 Preclinical trials in Uveal melanoma in USA (unspecified route), prior to June 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top